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Abstract
Objective: To assess the impact of antimicrobial stewardship programs (ASPs) in adult medical–surgical intensive care units (MS-ICUs) in Latin
America.
Design: Quasi-experimental prospective with continuous time series.
Setting: The study included 77 MS-ICUs in 9 Latin American countries.
Patients: Adult patients admitted to an MS-ICU for at least 24 hours were included in the study.
Methods: This multicenter study was conducted over 12 months. To evaluate the ASPs, representatives from all MS-ICUs performed a self-
assessment survey (0–100 scale) at the beginning and end of the study. The impact of each ASP was evaluated monthly using the following
measures: antimicrobial consumption, appropriateness of antimicrobial treatments, crudemortality, andmultidrug-resistant microorganisms
in healthcare-associated infections (MDRO-HAIs). Using final stewardship program quality self-assessment scores, MS-ICUs were stratified
and compared among 3 groups: ≤25th percentile, >25th to <75th percentile, and ≥75th percentile.
Results: In total, 77MS-ICU from 9 Latin American countries completed the study. TwentyMS-ICUs reached at least the 75th percentile at the
end of the study in comparison with the same number who remain within the 25th percentile (score, 76.1 ± 7.5 vs 28.0 ± 7.3; P < .0001).
Several indicators performed better in the MS-ICUs in the 75th versus 25th percentiles: antimicrobial consumption (143.4 vs 159.4 DDD per
100 patient days; P < .0001), adherence to clinical guidelines (92.5% vs 59.3%; P < .0001), validation of prescription by pharmacist (72.0% vs
58.0%; P < .0001), crude mortality (15.9% vs 17.7%; P < .0001), and MDRO-HAIs (9.45 vs 10.96 cases per 1,000 patient days; P = .004).
Conclusion: MS-ICUs with more comprehensive ASPs showed significant improvement in antimicrobial utilization.
(Received 28 August 2020; accepted 18 February 2021)
The introduction of antimicrobials has transformed medical practice
converting previously fatal infections into treatable diseases. Misuse
and overuse of antimicrobials comprise a significant cause of
emerging antimicrobial resistance (AMR).1 Although early and
appropriate treatment has been shown to reducemortality2 in patients
with severe sepsis or septic shock, 20%–50% of antimicrobials pre-
scribed in US hospitals are inappropriate or unnecessary.3–5
Furthermore, antimicrobial exposure increases the risk of adverse
events, drug interactions, superinfections, and the development of
multidrug-resistant organisms (MDROs), fungal infections,
Clostridiodes difficile infection (CDI), as well as healthcare costs.6–9
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Inappropriate use of antimicrobials has a negative impact not only on
the patient but also on the broader patient population through
increased rates of MDROs.10
Estimates indicate that >700,000 deaths occur worldwide each
year fromAMR, and this number is projected to reach 10million in
2050.11 The financial costs associated with treating these infections
reach many billions of dollars.1,12 The effective implementation of
antimicrobial stewardship programs (ASPs) has allowed a cost-
effective reduction in antimicrobial consumption, increasing
patient safety and reducingAMR.13,14 The implementation of strat-
egies for appropriate use of antimicrobials is a cornerstone in
reducing emergence and transmission of MDROs. Multiple guide-
lines have been published, proposing a framework to combat AMR
based on the development of robust infection control programs,
therapeutic committees, guidelines on antimicrobial management,
and monitoring and feedback of prescription patterns.15–18 This
framework contributed to the development of ASPs, which focus
on preprescription authorization and postprescription review and
feedback, which have succeeded at curbing resistance, decreasing
costs, and decreasing rates of CDI in US hospitals.19–21 However,
hospitals located in low- and middle-income countries (LMICs)
have different sets of challenges.22,23 Stories of modest success have
been reported around the world, but robust data are lacking,24 and
data on AMR and ASPs in Latin America are especially scarce.
In this study, we aimed to implement ASPs in adult medical-
surgical intensive care units (MS-ICUs) from Latin American
countries and to assess impact on appropriateness of antimicrobial
prescriptions, antimicrobial use, crude mortality, MDRO in health-
care-associated infections (MDRO-HAIs) and Clostridioides difficile
infections (CDIs).We hypothesized thatMS-ICUs with higher scores
in the final self-assessment would show improved indicators of appro-
priate antimicrobial use and improved patient outcomes.
Methods
Study design
The study included a network of hospitals recruited from 9 Latin
American countries. A nonrandom sample of 84 MS-ICUs from
tertiary-care hospitals in Latin America were invited by infectious
disease leaders from each country to voluntarily participate in the
project. We included facilities with an ASP team composed of an
infectious disease (ID) physician, a clinical pharmacist, and a
microbiologist. All study data were deidentified, and patient con-
sent was waived. Ethics approvals varied by country and were
obtained by participating hospitals on an individual basis. A cen-
tral ethics committee was enlisted at the coordinating center, the
Global Health Initiative at Henry Ford Health System,
Michigan. A data privacy document was made available for each
participating hospital.
The study was built using methodology from a prior study.25
The study was conducted over a 24-month period with a 6-month
preintervention period, a 12-month intervention period, and a 6-
month postintervention study period.
During the preintervention period, the members of the ASP
teams were trained through an online course. During this period,
each center completed a baseline self-assessment of their ASP
through a previously validated instrument (Supplementary
Material 1 online).25
During the 12-month intervention period and based on the
results of the baseline self-assessment, each center implemented
locally salient antimicrobial stewardship strategies in MS-ICUs
as part of the ASP. During this period, monthly surveys were
performed to measure the appropriateness of antimicrobial pre-
scription, antimicrobial consumption, mortality, and incidence
of MDRO-HAIs. The implementations of respective IPC strategies
were registered monthly. At month 6 during the intervention
period, an interim self-assessment using the same instrument
was performed to respectively determine which ASP strategies
had been implemented.
During the postintervention period, a final self-assessment was
performed to summarize the level of development achieved by the
ASP at each MS-ICU.
Data collection
All data were entered into a secured online database through a
central website developed for this study. A help desk and supple-
mentary documents were available there. The platform included
the online training course, participating center characteristics,
and standardized collection of study information. Data validation
included several integrated verifications with error and warning
messages to avoid duplicated and erroneous data entry and miss-
ing information. The system created monthly indicators and
graphics comparing data from all participating MS-ICUs. Each
investigator could monitor their own indicators in comparison
with the rest of centers.
The following variables were collected from each participating
hospital for analysis and comparison: affiliation type (public or pri-
vate, teaching or nonteaching), number of MS-ICU beds, full-time
equivalent for ASP team members, and the presence of an IPC
committee and/or a pharmacy committee.
The instrument used to evaluate the ASPs was based on the
CDC Core Elements checklist26 and contained a total of 74
indicators, grouped into 33 standards, 15 components, and 4
domains (Supplementary Material 1 online). We evaluated the
following domains: (1) leadership and coordination, (2) institu-
tional intervention strategies, (3) monitoring, and (4) education.
Partial scores for each domain and a global score were developed.
The results of the self-assessment of ASPs were finalized on a
scale from 0 to 100 points to allow institutional comparisons.
The means of the self-assessment score were grouped by percen-
tiles (≤25th, >25th to <75th, and ≥75th) for comparisons among
the MS-ICUs.
A standardized surveillance methodology was used to collect
data from antimicrobial prescriptions.25,27 Monthly 1-day preva-
lence surveys, including all inpatients who were in an MS-ICU
at 8:00 A.M. and who received at least 1 systemic antimicrobial,
were collected. Survey information included characteristics of
the patient (ie, age, gender, weight) and the antimicrobial prescrip-
tion (ie, therapeutic indication, unit dose, number of daily doses,
administration route, pharmacist validation, dose adjustments,
and therapeutic drug monitoring). Prescriptions were categorized
as treatment for community-acquired infections (CAIs), treatment
for healthcare-associated infections (HAIs), medical prophylaxis,
or surgical prophylaxis. Whether treatment was empirical or tar-
geted was also recorded.
We analyzed the following indicators of appropriateness of the
antimicrobial prescriptions: surgical prophylaxis <24 hours, vali-
dation of prescription by pharmacists, justification of prescription
in the medical record, compliance with clinical guidelines, pro-
spective audit and feedback, acceptance of ID physician recom-
mendation, aminoglycosides in a 1-day dose, no redundant
anaerobic therapy, de-escalation of therapy performed, and switch
from intravenous to oral route.
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Antimicrobial consumption was measured in defined daily
doses per 100 patient days (DDD per 100 PD) per month for sys-
temic antibacterials and antifungals (categories J01 and J02 from
the Anatomical Therapeutic Chemical classification system).28,29
To determine the impacts of the respective ASPs, monthly CDI,
MDRO-HAIs, and all-cause mortality in the MS-ICU were regis-
tered. Additionally, the respective implementations of the follow-
ing IPC strategies were registered: hand hygiene program, periodic
surveillance of MDRO-HAIs, policies for contact precautions and
environmental cleaning, daily chlorhexidine bathing, surveillance,
and bundles addressing device-associated infections.
Statistical analysis
The results of the self-assessment are shown as mean ± SD. The
paired Student t test was used to compare the initial and final
scores, and the Student t test was used to compare MS-ICUs. To
identify institutional characteristics associated with the level of
the ASP, a bivariate analysis was conducted using the final self-
assessment score as the outcome. Statistically associated variables
(P< .10) were introduced into a stepwisemultiple linear regression
model, and only those that were significantly associated (P < .05)
remained in the model.
Indicators for appropriateness of antimicrobial prescriptions
were presented as percentage of total prescriptions complying with
each indicator. Overall, crude mortality was expressed as monthly
death in the MS-ICU per 100 discharges. Cumulative compliance
of IPC strategies was calculated as percentage of the 12 months
each strategy was implemented. These variables were compared
using the χ2 statistic, and results are expressed as differences of
the percentages and their respective 95% CIs.
The total DDD per 100 PD of targeted antimicrobials, MDRO-
HAIs, and CDIs at the different MS-ICUs were compared as inci-
dence densities using the Poisson test.
A P value<.05 (2-tailed) was considered statistically significant.
For statistical analyses, we used SPSS version 22 software (IBM,
Chicago, IL).
Results
Of the 84 MS-ICUs that initially agreed to participate in the
project, 77 (91.7%) completed the study and 7 (8.3%) dropped
out. Of the participating sites, 45 were fromArgentina, 6 were from
Ecuador, 5 were from Colombia, 5 were from Uruguay, 5 were
from Brazil, 3 were from Chile, 3 were from Peru, 3 were from
Panama, and 2 were from Bolivia. Overall, 233 members of ASP
teams completed the online training course.
Self-assessment
The global scores of the initial and final self-assessments were 40.7
± 17.3 and 52.1 ± 19.2, respectively (difference, 11.3; 95% CI, 8.1 to
14.6; P < .0001), and all 4 domains showed a significant improve-
ment over the course of the study (Table 1).
The following components showed significant improvement in
the final self-assessments: institutional support, staff commitment
from other key departments, information technology assistance,
institutional policies, interventions to optimize antimicrobial
use, monitoring of antimicrobial use, appropriateness, impact
indicators, and education and training for prescribers and for
patients and relatives (Table 1).
Only Argentina, Colombia, Panama, and Uruguay showed a
significant improvement in the global scores per country when
the initial and final self-assessments were compared (Table 2).
The following institutional characteristics associated with a
higher global score in the final self-assessment in the bivariate analy-
sis: private versus public institution (56.2 vs 47.6; P = .048); at least
15 beds in the MS-ICU (58.7 vs 48.5; P = .024); full-time infection
preventionist (53.1 vs 25.9; P = .015); at least 6 meetings per year of
the IPC committee (55.4 vs 43.1; P = .011); and at least 6 meetings
per year of the pharmacy committee (58.9 vs 47.4; P = .009). In the
stepwise multiple linear regression, only facilities with at least 15
beds at theMS-ICU and at least 6meetings per year of the pharmacy
committee showed an independent significant statistical association
(P = .042 and P = .015, respectively).
When institutions were stratified into 3 groups according to the
global score of the final self-assessment (ie, ≤25th,>25th to <75th,
≥75th percentiles), only those centers in the >25th to <75th per-
centile and ≥75th percentile groups showed a significant improve-
ment in their ASPs when the final and initial self-assessments were
compared (52.1 vs 38.1 and 76.1 vs 59.2, respectively; both
P< .0001). Centers within the 25th percentile did not show signifi-
cant improvement in their ASPs (28.0 vs 27.1; P = .7077).
Antimicrobial prescriptions, antimicrobial consumption, and
appropriateness indicators
Data from the point-prevalence surveys showed that of 10,058
MS-ICU inpatients, 6,019 inpatients (59.8%) received 10,523 anti-
microbial prescriptions (1.75 antimicrobial per patient on antimi-
crobial treatment). Of these 10,523 prescriptions, 5,194 (49.4%)
corresponded to HAIs treatment; 2,992 (28.4%) for CAIs; 590
(5.6%) surgical prophylaxis; 458 (4.4%) for medical prophylaxis;
and 1,289 (12.2%) for indications not classified. Targeted treat-
ments were significantly more common for HAIs than for CAIs
(43.9% vs 25.1%; P < .0001).
Among all antibiotics prescribed for CAIs, the following were
most frequently prescribed: 663 prescriptions (28.9%) were for pen-
icillins with a β-lactamase inhibitor, 202 (8.8%) were for merope-
nem, 199 (8.7%) were for vancomycin, and 184 (8.0%) were for a
third-generation cephalosporin (Fig. 1). Among the prescriptions
for penicillins with a β-lactamase inhibitor, 314 prescriptions
(13.7%) were for piperacillin with a β-lactamase inhibitor and 312
(13.6%) were for amoxicillin with a β-lactamase inhibitor. The fol-
lowing antibiotics were most commonly prescribed for HAIs: 1,242
prescriptions (23.9%) were for carbapenems, 840 (16.2%) were for
glycopeptides, 758 (14.6%) were for penicillins with a β-lactamase
inhibitor, and 597 (11.5%) were for polymyxins (Fig. 1).
Among the 426 systemic antifungal prescriptions, triazole drugs
were the most frequently prescribed: 55 of 87 CAIs (2.4% of total
prescriptions) and 177 of 339 HAIs (3.4% of total prescrip-
tions) (Fig. 1).
Throughout the 12-month study period, 464,770 DDDs were
consumed throughout 304,700 patient days in MS-ICUs (152.5
DDD per 100 PD). The following antimicrobial groups were most
frequently consumed: penicillins with a β-lactamase inhibitor (34.0
DDD per 100 PD), followed by carbapemens (30.4 DDD per 100
PD), glycopeptides (13.2 DDD per 100 PD), and polymyxins (9.7
DDD per 100 PD).
The frequency distribution of antimicrobial consumption
between MS-ICUs stratified by the final self-assessment into the
3 percentile groups are shown in Figure 2. Consumption of pen-
icillin with a β-lactamase inhibitor, carbapenem, glycopeptide,
third-generation cephalosporin, and aminoglycoside were lower
in MS-ICUs in the ≥75th percentile.
The percentage of patients receiving at least 1 antimicrobial and
the number of antimicrobials per patient on antimicrobial
Infection Control & Hospital Epidemiology 3
Downloaded from https://www.cambridge.org/core. 10 May 2021 at 16:25:51, subject to the Cambridge Core terms of use.
Table 1. Comparison at the Domains Between Initial and Final Self-Assessment
Initial Final
Percentiles Percentiles
Domains/Components Mean ± SD 10th 25th 50th 75th 90th Mean ± SD 10th 25th 50th 75th 90th Difference of Means 95% CI P Value
Leadership and coordination 56.5±21.2 30.0 41.2 57.6 69.8 85.6 62.7±21.2 36.6 45.2 63.8 83.1 92.0 6.2 1.8 to 10.5 .006
Institutional support 38.3±28.5 0.0 16.7 33.3 66.7 73.3 48.1±31.4 0.0 16.7 50.0 66.7 100.0 9.7 3.4 to 16.1 .003
Accountability 62.3±30.2 25.0 50.0 50.0 100.0 100.0 69.5±27.7 25.0 50.0 75.0 100.0 100.0 7.1 −0.3 to 14.6 .060
Staff commitment from other key departments 55.6±25.4 30.0 40.0 50.0 80.0 90.0 62.7±25.4 30.0 40.0 60.0 90.0 100.0 7.1 0.8 to 13.5 .028
Information technology assistance 70.1±29.2 26.7 66.7 83.3 83.3 100.0 77.1±27.2 33.3 66.7 83.3 100.0 100.0 6.9 0.8 to 13.2 .026
Integration with other institutional committees 50.6±32.8 0.0 33.3 50.0 83.3 100.0 55.6±31.9 16.7 33.3 50.0 83.3 100.0 5.0 −1.2 to 11.2 .110
Integration with other institutional programs 56.5±32.5 0.0 25.0 50.0 75.0 100.0 61.0±31.8 25.0 50.0 50.0 100.0 100.0 4.5 −1.0 to 10.1 .109
Scope of the ASP 61.9±29.7 25.0 37.5 62.5 87.5 100.0 64.8±27.9 25.0 50.0 62.5 87.5 100.0 2.9 −3.6 to 9.4 .374
Institutional intervention strategies 45.6±21.3 21.4 29.5 42.5 61.3 74.2 59.8±21.4 32.5 44.7 58.8 77.1 87.3 14.2 10.0 to 18.3 .000
Institutional policies 47.1±29.6 10.0 19.2 46.2 65.4 93.9 65.3±26.8 38.5 46.2 61.5 92.3 100.0 18.3 12.8 to 23.8 .000
Interventions to optimize antimicrobial use 44.2±23.0 16.7 27.8 44.4 61.1 77.8 54.2±23.4 22.2 33.3 55.6 72.2 83.3 10.0 5.5 to 14.6 .000
Monitoring 42±21.6 14.6 24.3 39.6 58.3 70.2 55.6±21.7 23.8 42.4 54.9 70.8 84.8 13.7 9.7 to 17.6 .000
Antimicrobial use indicators 28.6±26.5 0.0 0.0 25.0 50.0 67.5 42.2±29.1 0.0 25.0 50.0 62.5 80.0 13.6 8.5 to 18.8 .000
Appropriateness indicators 28.3±25.0 0.0 8.3 16.7 50.0 66.7 39.0±28.4 8.3 16.7 33.3 58.3 78.3 10.6 4.9 to 16.3 .000
Impact indicators 63.1±32.5 22.2 33.3 61.1 94.4 100.0 79.1±25.1 50.0 61.1 88.9 100.0 100.0 16.0 9.2 to 22.7 .000
Institutional reporting 47.9±27.2 12.5 25.0 50.0 62.5 80.0 62.3±29.4 12.5 50.0 62.5 87.5 100.0 14.4 8.1 to 20.8 .000
Education 18.8±17.2 0.0 0.0 15.0 30.0 40.0 30.1±25.8 0.0 5.0 25.0 50.0 62.0 11.4 6.1 to 16.6 .000
Education and training to prescribers 31.0±27.0 0.0 0.0 30.0 40.0 80.0 44.0±33.7 0.0 10.0 50.0 70.0 90.0 13.0 6.3 to 19.7 .000
Education to patient and relatives 6.5±16.9 0.0 0.0 0.0 0.0 50.0 16.2±24.3 0.0 0.0 0.0 50.0 50.0 9.7 3.4 to 16.1 .003
Global score 40.7±17.3 20.1 29.0 38.5 54.3 66.2 52.1±19.2 27.3 38.0 52.4 66.6 77.5 11.3 8.1 to 14.6 .000
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treatment were significantly lower in theMS-ICUs that reached the
≥75th percentile in comparison with those that remained within
the 25th percentile at the final self-assessment (Table 3). The
MS-ICUs that reached the ≥75th percentile had a significantly
lower total antimicrobial consumption than those that remained
in the 25th percentile (143.4 vs 159.4 DDD per 100 PD; P <
.0001) (Table 3).
The following appropriateness indicators performed better
among MS-ICUs that reached the ≥75th percentile: validation of
prescription by pharmacist, justification of prescription in the
medical record, compliance with clinical guidelines, prospective
audit with feedback, acceptance of ID physician recommendation,
no redundant anaerobic therapy, de-escalation, and targeted treat-
ments (Table 3). Surgical prophylaxis of <24 hours, therapeutic
monitoring of vancomycin, aminoglycosides on 1-day dose, and
switches from the intravenous to oral route did not show statistical
difference.
Impact indicators
The cumulative impact indicators during the 12 months of the
study showed that crude mortality and MDRO-HAIs were signifi-
cantly lower in MS-ICUs in the ≥75th percentile than those in the
25th percentile. Only CDI was significantly higher in MS-ICUs in
the ≥75th percentile (Table 3).
IPC strategies
MS-ICUs in the ≥75th percentile showed a significant higher fre-
quency of IPC strategies implemented than those units within the
25th percentile (Table 4).
Discussion
This is the first multicenter study in Latin American MS-ICUs to
evaluate antimicrobial prescription appropriateness, consumption
and impact indicators in relation to the level of ASP development.
Overall, 76.6% of the centers showed a significant improvement in
their ASP scores. However, only 26.0% reached the 75th percentile
in the final self-assessment, and 23.4% centers did not improve
their global scores along the study.
The domain “leadership and coordination” scored highest at
the final self-assessment, followed by “intervention strategies”
and “monitoring.” “Education” was the domain with the lowest
score. The latter represents an opportunity to develop and imple-
ment new strategies to improve education and training to prescrib-
ers and to patient and relatives. These findings are consistent with a
previous study analyzing 4,184 US acute-care hospitals through the
2014 National Healthcare Safety Network Annual Hospital Survey,
which reported that only 39.2% of institutions have an ASP meet-
ing all 7 core elements.30 In addition, written support or salary
funding were significantly associated with having a comprehensive
ASP.30 In a cross-sectional study including 103 hospitals in Central
and South America, the lack of hospital administration, lack of
information technology support, and opposition from prescribers
were stated as main barriers to the development of ASPs.31 More
recently, in a survey conducted in 27 Latin American hospitals,
40.7% of respondent hospitals did not have a written statement
supporting an ASP, and 51.9% reported no financial support for
ASP practices. In addition, only 26% of laboratories agreed to per-
form testing for MDROs, and only 40.7% of hospitals included
education to prescribers on improving antibiotic use.32
Our findings confirm that ASPs are often only partially imple-
mented in Latin American hospitals. This issue represents a very
important challenge because institutional support, interventions to
optimizing antibiotic use, monitoring and reporting processes, as
well as physician education, are necessary to implement an ASP
effectively.15
The feasibility of doing a prevalence survey has been demon-
strated in previous studies.25,27 This methodology has allowed hos-
pitals in LMICs to assess antibiotic prescribing patterns and to
collect information about antibiotic resistance for the first time.
In that sense, measurement of appropriateness of antimicrobial
prescription is essential for monitoring and reporting ASPs.
We observed lower antimicrobial resistance in the higher per-
centile group, and this finding could be related to lower consump-
tion of antibiotics in theMS-ICUs that have amore comprehensive
ASP. As in a previous study, we found that targeted treatments
were more common for HAIs than CAIs.27 In addition, we
observed a high rate of empiric use of carbapenems and vancomy-
cin and a low rate of de-escalation. High rates of extended-
spectrum β lactamase, methicillin-resistant Staphylococcus aureus,
and carbapenem-resistant Enterobacteriaceae infections are lead-
ing to increased use of carbapenems, vancomycin, and







10th 25th 50th 75th 90th Mean±SD 10th 25th 50th 75th 90th Difference of Means 95% CI
P
Value
Argentina 45 42.1±15.9 26.3 29.2 36.1 54.3 66.8 50.6±15.7 30.1 39.8 49.8 64.0 69.7 8.5 4.7 to 12.2 .000
Bolivia 2 45.1±31.7 70.5±9.6 25.5 : : : .351
Brazil 5 61.0±15.3 49.6 56.3 57.2 59.8 75.8 67.8±21.6 44.0 56.1 77.8 80.3 85.5 6.9 −9.6 to 23.3 .311
Chile 3 26.3±10.1 17.9 22.1 29.0 31.9 33.6 26.9±10.7 18.0 22.3 29.5 32.8 34.7 0.6 −0.9 to 2.1 .245
Colombia 5 52.2±11.8 39.3 42.4 55.7 62.5 62.9 77.3±13.7 61.9 65.3 86.4 87.0 87.6 25.0 0.9 to 49.2 .045
Ecuador 6 37.0±11.6 26.2 38.7 40.6 43.7 44.2 55.4±23.7 29.4 38.9 58.4 73.5 78.6 18.4 −0.8 to 37.7 .057
Panama 3 45.0±10.4 36.5 41.7 50.2 51.0 51.5 56.5±14.6 44.6 52.0 64.3 65.0 65.3 11.5 0.4 to 22.6 .047
Peru 3 23.6±9.2 16.0 20.3 27.4 28.9 29.7 41.1±22.2 23.0 34.3 53.0 53.9 54.4 17.5 −54.7 to 89.7 .407
Uruguay 5 15.1±7.2 8.7 12.7 14.0 16.9 22.3 31.7±7.0 26.9 27.9 30.1 30.4 38.5 16.6 13.3 to 19.9 .000
Note. MS-ICU, medical-surgical intensive care unit; SD, standard deviation; CI, confidence interval.
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Fig. 1. Proportion of antimicrobials prescribed for systemic use in community-acquired (n=2292) and healthcare-associated (n=5194) infections among adult patients in
medical-surgical ICU.
Fig. 2. Annual use of systemic antimicrobials in adult patients in medical-surgical ICU (MS-ICU) expressed as defined daily doses (DDDs) per 100 patient-days stratified by the
global score of the final self-assessment.
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polymyxins.27,33–35 These findings represent an opportunity to pro-
mote new and rapid diagnostic tests to improve empiric
treatments.36
In our study, MS-ICUs that reached the 75th percentile showed
improvements in antimicrobial prescription appropriateness, anti-
microbial consumption, and impact indicators compared to those
that remained within the 25th percentile. Only CDI rates were sig-
nificantly higher at MS-ICUs above the 75th percentile, likely
related to better detection, as well as other risk factors such as con-
sumption of proton pump inhibitors, which were not evaluated in
this study.37 In addition, higher compliance with IPC strategies was
associated with ASPs that are more comprehensive.
This study has several limitations. Participation was voluntary,
whichmay have biased participation to hospitals with an interest in
antibiotic stewardship. The restriction of the study toMS-ICUmay
limit the generalizability of the results, and overrepresentation of
Argentinean hospitals may limit more generalizable conclusions.
The strengths of the project include the prospective study design,
findings of improved antibiotic use, better outcomes, and descrip-
tion of a model that is practical for the LMIC setting.
Based on previous experience, we limited our project to adult
inpatients admitted to MS-ICUs. We restricted the study to adult
patients because of difficulties in performing data collection using
days of therapy as the measure of antimicrobial consumption in
many Latin American institutions. Although, DDD is a useful indi-
cator in the adult population, it is not useful for pediatric
patients.25,29 Another reason to constrain the study to MS-ICUs
was to enhance feasibility and sustainability because a limited
number of human resources are involved in development, imple-
mentation, and monitoring ASPs in many hospitals located in low-
and middle- and lower-income countries.31 In addition, AMR and
the challenges of appropriateness of antimicrobial use aremore fre-
quent in ICUs than in general wards.38,39
In summary, our results suggest that MS-ICUs with ASPs with
higher global scores in the final-self assessment showed improved
appropriateness and impact indicators and lower antimicrobial
Table 3. Indicators Comparison Between MS-ICU Stratified by the Global Score of the Final Self-Assessment
Indicatorsa
Final Percentile Group, %b
≤25th <75th >25th ≥75th
Comparison Between ≥75th vs ≤25th
Percentiles
(n=20) (n=37) (n=20) Differences 95% CI P Value
Self-assessment final score (mean±SD) 28.0±7.3 52.1±8.6 76.1±7.5 48.1 43.4 to 52.8 .000
Antimicrobial prescription
% of patients receiving at least 1 antimicrobial 62.6 61.0 56.7 −5.9 −8.6 to −3.1 .000
No. of antimicrobials per patient on antimicrobial treatment 1.74 1.82 1.64 −0.10 −0.19 to −0.05 .004
Appropriateness indicators
Surgical prophylaxis <24 hc 46.2 59.0 51.5 5.4 −4.8 to 15.5 .352
Validation of prescription by pharmacistsc 58.0 58.6 72.0 14.0 11.4 to 16.6 .000
Justification of prescription in the medical recordc 94.7 97.2 97.6 2.9 1.8 to 4.0 .000
Compliance with clinical guidelinesc 59.3 72.2 92.5 33.2 30.9 to 35.5 .000
Prospective audit with feedbackc 76.2 87.9 86.1 9.9 7.7 to 12.1 .000
Acceptance of (ID) physician recommendationc 72.3 89.6 94.8 22.5 19.7 to 25.2 .000
Therapeutic monitoring of vancomycinc 24.4 33.5 25.0 0.6 −15.6 to 16.9 .882
Aminoglycosides on 1-day dosec 91.6 85.5 93.2 1.6 5.3 to 8.5 .839
No redundant anaerobic therapyc 0.96 0.80 0.26 −0.70 −0.03 to −0.75 .039
De-escalationc 3.8 5.2 8.2 4.4 3.0 to 5.7 .000
Switch from intravenous to oral route 37.9 35.8 35.2 −2.8 −18.6 to 13.1 .867
Targeted treatmentsc 27.6 35.9 39.5 12.0 9.2 to 14.7 .000
Antimicrobial use (DDDs per 100 patient daysd) 159.4 156.5 143.4 −16.0 −17.2 to −14.7 .000
Impact indicators
MDRO in healthcare-associated infections (cases per 1,000 patient dayse) 10.96 13.53 9.45 −1.52 −2.56 to −0.48 .004
CDIs (cases per 1,000 patient days) 0.19 0.25 0.57 0.37 0.19 to 0.56 .000
Crude mortality (events per 100 discharges) 17.7 16.0 15.9 −1.8 −2.8 to −0.8 .000
Note. MS-ICU, medical-surgical intensive care unit; CI, confidence interval; SD, standard deviation; ID, infectious diseases; DDD, defined daily dose; MDRO, multidrug-resistant organism; CDI,
Clostridioides difficile infection.
aCumulative indicators from July 2018 to June 2019.
bPercent unless otherwise indicated.
cAppropriateness rate: no. of prescriptions complying with the indicator × 100/total prescriptions of this category.
dAntimicrobial categories J01 and J02.
eMDROs: methicillin-resistant S. aureus; vancomycin-resistant Enterococcus; extended-spectrum β-lactamase Enterobacteriacea; carbapenem-resistant Enterobacteriacea; carbapenem-
resistant P. aeruginosa and Acinetobacter spp.
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consumption than those with lower scores. MS-ICUs with more
comprehensive ASPs showed significant improvement in antimi-
crobial utilization.
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Table 4. Infection Prevention and Control Strategies Implemented at MS-ICUs Stratified by the Global Score of the Final Self-Assessment
Indicatorsa
Final Percentile Group, %
≤ 25th <75th to >25th ≥75th
Comparison Between the ≥75th vs ≤25th
Percentiles
(n=20) (n=37) (n=20) Difference, % 95% CI P Value
Hand hygiene program 82.9 95.0 100.0 17.1 12.3 to 21.8 .000
Surveillance of hand hygiene adherence 68.8 69.9 88.8 19.9 12.3 to 27.5 .000
Surveillance of MDRO-HAI 61.7 82.0 88.3 26.7 19.3 to 34.0 .000
Policy for contact precautions 97.1 99.3 100.0 2.9 0.8 to 5.1 .022
Contact precautions for CRE 98.7 98.0 100.0 1.3 −0.1 to 2.7 .236
Contact precautions for CDI 92.7 83.9 96.3 3.5 −0.6 to 7.7 .136
Policy for environmental cleaning 93.3 98.0 100.0 6.7 3.5 to 9.8 .000
Measurement of environmental cleaning effectiveness 34.4 62.8 68.8 34.4 25.8 to 42.9 .000
Policy for daily chlorhexidine bathing 83.3 89.9 95.4 12.1 6.7 to 17.5 .000
Use of cloths impregnated with chlorhexidine for daily bathing 55.0 74.2 76.9 21.9 13.1 to 30.7 .000
Bundle for CLABSI 67.5 75.9 95.0 27.5 21.0 to 34.0 .000
Surveillance of CLABSI 81.5 89.9 100.0 18.5 12.5 to 24.5 .000
Bundle for CAUTI 65.8 72.1 91.3 25.4 18.4 to 32.4 .000
Surveillance of CAUTI 81.6 90.6 98.6 17.0 10.8 to 23.2 .000
Bundle for VAP 80.8 78.2 100.0 19.2 14.2 to 24.1 .000
Surveillance of VAP 87.1 91.1 99.2 12.1 7.2 to 16.9 .000
Note. MS-ICU, medical-surgical intensive care unit; CI, confidence interval; MDRO multidrug-resistant organisms: methicillin-resistant Staphylococcus aureus; vancomycin-resistant
Enterococcus; extended-spectrum β-lactamase Enterobacteriacea; carbapenem-resistant Enterobacteriacea; carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp.; CDI,
Clostridioides difficile infection. CLABSI, catheter-associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAP, ventilator-associated pneumonia; HAI, healthcare-
associated infection.
aCumulative compliance from July 2018 to June 2019.
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